

Iowa Department of Human Services

FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

Request for Prior Authorization LONG-ACTING OPIOIDS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

	<u> </u>	<u> </u>	
IA Medicaid Member ID #	Patient name		DOB
Patient address	.1		
Provider NPI	Prescriber name		Phone
			T Hollo
Prescriber address			Fax
Pharmacy name	Address		Phone
Prescriber must complete all inform	nation above. It must be legible, correc	t, and complete or	form will be returned.
Pharmacy NPI	Pharmacy fax	NDC	
the patient's risk for opioid addiction of the common adverse effects and sconsidered for FDA approved dosing document the following: a. The risks and b. Documentation as to why con provided, if appropriate. If criteria for will be considered if the following critunctioning; and 2) Prescriber has redetermined continued use of a long-benzodiazepines, the prescriber mushas been discussed with the patient,	ne if use of a long-acting opioid is appropriate and misuse prior to requesting serious adverse effects of opioids. 8) R intervals; and 9) For patients taking c of using opioids and benzodiazepines current use is medically necessary is proceed to coverage are met, an initial authorizate teria are met: 1) Patient has experience viewed the patient's use of controlled acting opioid is appropriate for this ment document the following: a. the risks of and b. Documentation as to why conc	g prior authorization equests for long-a concurrent benzoding concurrently has brovided; and c. A concurrent in substances on the mber; and 3) For pof using opioids ar urrent use is medical.	n; and 7) Patient has been informed cting opioids will only be azepines, the prescriber must been discussed with the patient; plan to taper the benzodiazepine is or 3 months. Additional approvals pain control and level of lowa PMP website and has patients taking concurrent bed benzodiazepines concurrently cally necessary is provided; and c.
is provided that use of these agents	s provided, if appropriate. The required would be medically contraindicated.	triais may be over	riaden when documented evidence
Drug Name:	Strength:		
Dosage Instructions:		Quantity:	Days Supply:
Diagnosis:			
	pies (such as physical therapy, weight los apies such as cognitive behavior therapy		ies such as manipulation, massage,
Non-Pharmacological Treatment Trial #	1:		
·	ailure reason:		
Non-Pharmacological Treatment Trial #	2:		
Trial Dates: F			
	ailure reason:		
Document 2 nonopioid pharmacolog	ailure reason:ic therapies (acetaminophen, NSAIDs, o		
-		r selected antidepre	ssants and anticonvulsants)
Nonopioid Pharmacologic Trial #1: Nam	ic therapies (acetaminophen, NSAIDs, o	r selected antidepre	ssants and anticonvulsants)
Nonopioid Pharmacologic Trial #1: Nam Failure reason:	ic therapies (acetaminophen, NSAIDs, one/Dose:	r selected antidepre	ssants and anticonvulsants) Dates:
Nonopioid Pharmacologic Trial #1: Nam Failure reason: Nonopioid Pharmacologic Trial #2: Nam	ic therapies (acetaminophen, NSAIDs, one/Dose:	r selected antidepre Trial Trial	ssants and anticonvulsants) Dates:

Iowa Department of Human Services

Request for Prior Authorization-Continued LONG-ACTING OPIOIDS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Document 1 preferred long-acting opioid treatment failure including drug name, so	trength, exact date ranges and failure reason:
Preferred Long-Acting Narcotic Trial: Name/Dose:	Trial Dates:
Failure reason:	
*Please refer to the methadone dosing guidelines located at www.iadur.org under the Re	eport Archive tab.
Prescriber review of patient's controlled substances use on the lowa PMP website	e: No Yes Date Reviewed:
Is long-acting opioid use appropriate for patient based on PMP review and patient $\hfill \square$ No $\hfill \square$ Yes	t's risk for opioid addiction, abuse and misuse?
Has patient been informed of the common adverse effects (constipation, dry mout tolerance, physical dependence, and withdrawal symptoms when stopping opioid overdose and development of a potentially serious opioid use disorder) of opioids	s) and serious adverse effects (potentially fatal
□ No □ Yes	
Patients taking concurrent benzodiazepines:	
Have the risks of using opioids and benzodiazepines concurrently been discussed with t	the patient?
Medical necessity for concurrent use:	
Provide plan to taper the benzodiazepine or medical rationale why not appropriate:	
Renewals	
Has patient experienced improvement in pain control and level of functioning?	
□ No □ Yes (describe):	
Updated prescriber review of patient's controlled substances use on the Iowa PMI ☐ No ☐ Yes Date Reviewed:	P website (since initial request):
Patients taking concurrent benzodiazepines:	
Have the risks of using opioids and benzodiazepines concurrently been discussed with t	the patient?
Medical necessity for concurrent use:	
Provide plan to taper the benzodiazepine or medical rationale why not appropriate:	
Attach signed chronic opioid therapy management plan between the prescriber as	nd patient.
Prescriber signature (Must match prescriber listed above.)	Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

470-4409 (Rev. 7/19) Page 2 of 2